Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of the cases. Despite advancements in targeted therapies and immunotherapies, many patients still rely on chemotherapy, highlighting the need for innovativ...
Saved in:
| Main Authors: | Saqib Raza Khan, Daniel Breadner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/4/206 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bispecific antibody for lung cancer: mechanisms and clinical insights
by: Wei Chen, et al.
Published: (2025-05-01) -
Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights
by: Wei Chen, et al.
Published: (2025-07-01) -
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer
by: Junxu Wen, et al.
Published: (2025-04-01) -
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01) -
An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
by: Latifa Zekri, et al.
Published: (2020-12-01)